Beatrice Detti
University of Florence
CancerInternal medicineRadiologyUrologySurgeryOncologyRetrospective cohort studyProspective cohort studyCyberknifeChemotherapyTemozolomideAndrogen deprivation therapyConcomitantProstatectomyProstate cancerRadiosurgeryToxicityStereotactic body radiation therapyNuclear medicineIn patientRadiation therapyBreast cancerMedicine
134Publications
20H-index
1,339Citations
Publications 134
Newest
#1Beatrice DettiH-Index: 20
#2Silvia ScocciantiH-Index: 19
Last. Lorenzo LiviH-Index: 28
view all 10 authors...
BACKGROUND High-grade gliomas are among the most aggressive central nervous system primary tumors, with a high risk of recurrence and a poor prognosis. Re-operation, re-irradiation, chemotherapy are options in this setting. No-best therapy has been established. Bevacizumab was approved on the basis of two Phase 2 trials that evaluated its efficacy in patients with recurrent glioblastoma. MATERIALS AND METHODS We have retrospectively review data of patients with high-grade glioma treated at our i...
Source
#1Beatrice DettiH-Index: 20
#2G. StocchiH-Index: 2
Last. Lorenzo LiviH-Index: 28
view all 10 authors...
BACKGROUND Patients who received a kidney transplant (KT) are described in literature as a group with a higher incidence of malignant neoplasms compared to the general population. Cancer development after KT has become a major issue, as a remarkable percentage of patients are diagnosed with cancer. Treatment of prostate cancer (PCa) in renal transplant recipients (RTRs) is a challenging issue that has been discussed by many authors over the years, but evidence is sparse and often includes confli...
Source
#1E. MazzeoH-Index: 8
#2Luca TriggianiH-Index: 15
Last. Stefano Maria MagriniH-Index: 25
view all 22 authors...
BACKGROUND AND PURPOSE Two previous "Patterns Of Practice" surveys (POP I and POP II), including more than 4000 patients affected by prostate cancer treated with radical external beam radiotherapy (EBRT) between 1980 and 2003, established a "benchmark" Italian data source for prostate cancer radiotherapy. This report (POP III) updates the previous studies. METHODS Data on clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011 were collected and compare...
Source
#1Luca TriggianiH-Index: 15
#2Rosario MazzolaH-Index: 19
Last. Stefano Maria MagriniH-Index: 25
view all 21 authors...
The aim of the present study was to explore the potential impact of upfront metastases-directed therapy (MDT) in terms of prolongation of castration-sensitive phase in a series of oligorecurrent castration-sensitive prostate cancer (PC) patients. The present article is a multicenter retrospective study. The population of interest was castrate-sensitive oligorecurrent PC, defined as the presence of 1-3 uptakes in non-visceral sites such as bones or nodes detected by means of 18F-Choline PET/CT or...
Source
#1Beatrice DettiH-Index: 20
#2Angela Sardaro (University of Bari)H-Index: 8
Last. Lorenzo LiviH-Index: 28
view all 10 authors...
Abstract Penile metastasization is an uncommon condition, mostly derived from primitive advanced abdominal cancers, with disabling symptoms. Palliative treatment, in reason of poor prognosis patients, is frequently surgical with destructive management. We report two cases of penile metastasis, from primitive prostatic adenocarcinoma and primitive urothelial carcinoma, effectively managed with radiation treatment at our institution. A three-dimensional conformal radiation therapy with 42 Gy to th...
Source
#1Giulio Francolini (UniFI: University of Florence)H-Index: 13
#2Pietro Garlatti (UniFI: University of Florence)H-Index: 4
Last. Lorenzo Livi (UniFI: University of Florence)H-Index: 28
view all 20 authors...
118Background: Androgen Receptor Targeted Agents (ARTA) represent one of the main treatment options for metastatic castrate resistant prostate cancer (mCRPC). Addition of stereotactic radiation the...
Source
#1Beatrice DettiH-Index: 20
#2Gianluca Ingrosso (University of Perugia)H-Index: 13
Last. Lorenzo LiviH-Index: 28
view all 14 authors...
MicroAbstract Management of prostate cancer should be adapted in response to the COVID-19 pandemic. A practical additional document on treatment of this tumor was developed in according to the recent recommendations of the European Association of Urology. In conclusion, the challenge should concern a correct management of the oncologic patient, reducing the risk of spreading the virus without worsening tumor prognosis.
Source
#1Gianluca Ingrosso (University of Perugia)H-Index: 13
#2Carlotta Becherini (UniFI: University of Florence)H-Index: 9
Last. Beatrice Detti (UniFI: University of Florence)H-Index: 20
view all 13 authors...
Abstract Objective To conduct a systematic review and meta-analysis of the role of SBRTdrug combination in patients affected by mRCC and associated oncologic outcomes and toxicity profiles. Evidence acquisition We performed a critical review of the Pubmed, Medline, and Embase databases from January 1, 2000 through April 30, 2020 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified Delphi tool. Evidenc...
Source
#1Giulio Francolini (UniFI: University of Florence)H-Index: 13
#2Beatrice Detti (UniFI: University of Florence)H-Index: 20
Last. Gianluca Ingrosso (University of Perugia)H-Index: 13
view all 17 authors...
AIMS 68Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA 7 (p = 0.004) and TTR < 29.5 months (p = 0.003). CONCLUSIONS PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.
1 CitationsSource
#1Gianluca Ingrosso (University of Perugia)H-Index: 13
#2Beatrice Detti (UniFI: University of Florence)H-Index: 20
Last. Maurizio Valeriani (Sapienza University of Rome)H-Index: 17
view all 19 authors...
OBJECTIVES To report outcomes of stereotactic body radiotherapy (SBRT) in metastatic castration-resistant prostate cancer (mCRPC) patients with oligoprogression (≤ 5 metastases) during first-line treatment with androgen receptor-targeted therapy (ARTT). PATIENTS AND METHODS Retrospective multi-institutional analysis of mCRPC patients treated with SBRT to oligoprogressive lesions during ARTT. End-points were time to next-line systemic treatment (NEST), radiological progression-free survival (r-PF...
1 CitationsSource